Stock of the Day

May 18, 2020

Bio-Rad Laboratories (BIO)

$380.75
-$5.37 (-1.4%)
Market Cap: $10.32B

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Today's Trend

Bio-Rad Laboratories, Inc. (NYSE: BIO) is receiving mixed analyst estimate changes, with the overall outlook carrying a mildly negative tilt. The stock is trading near its 52-week high, but the latest revisions suggest investors are weighing stronger near-term expectations against weaker longer-term earnings forecasts.

  • Zacks Research raised its FY2026 EPS estimate to $9.71 from $9.42 and increased its Q2 2027 forecast to $2.23 from $2.21. It also lifted its Q1 2028 estimate to $2.26 from $1.96, providing some support for the shares.
  • Zacks Research maintained a “Hold” rating on Bio-Rad Laboratories. The firm’s current full-year estimate is reported between $9.14 and $9.28, indicating limited conviction despite the individual forecast adjustments.
  • Zacks Research reduced its Q3 2027 EPS estimate to $2.25 from $2.39, its Q4 2027 estimate to $2.32 from $2.48, and its FY2027 forecast to $9.02 from $9.30. These reductions point to softer expected earnings momentum.
  • The firm also cut its FY2028 EPS estimate to $9.26 from $9.87 and lowered its Q2 2028 forecast to $2.32 from $2.46. The longer-term cuts may weigh on sentiment because they imply slower profit growth than previously expected.

Overall, the estimate revisions are likely creating volatility for Bio-Rad Laboratories (BIO). Upward changes to FY2026 and Q1 2028 earnings offer near-term encouragement, but the larger reductions to FY2027 and FY2028 forecasts are a negative signal. With shares already trading at elevated levels and analysts retaining a Hold rating, investors may focus on whether Bio-Rad can deliver earnings growth sufficient to justify its valuation.

← Previous Stock of the DayNext Stock of the Day →